This multi-center study of 519 patients with myelodysplastic syndrome (MDS) or oligoblastic acute myeloid leukemia (<30% marrow blasts) demonstrated that both monosomal karyotype and revised International Prognostic Scoring System (IPSS-R) risk category are important factors predicting outcomes of allogeneic hematopoietic cell transplantation (HCT). Patients had a median age of 48 years (range 17-72) and were transplanted between 2000 and 2011. In a multivariate analysis, high-risk IPSS-R category and monosomal karyotype were independently associated with relapse and lower survival. The researchers concluded that “allogeneic HCT offers optimal eradication of myelodysplastic hematopoiesis when the procedure is performed before MDS patients progress to advanced disease stages.”
Della Porta MG, et al. BloodChoose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
IPSS-R and Monosomal Karyotype Predict HCT Outcomes in MDS and AML
Mar 2014